Kezar Life Sciences (KZR)
(Delayed Data from NSDQ)
$0.82 USD
+0.01 (0.96%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $0.82 0.00 (-0.46%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
KZR 0.82 +0.01(0.96%)
Will KZR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for KZR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KZR
What Makes Kezar Life Sciences (KZR) a New Buy Stock
KZR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KZR
H.C. Wainwright Sticks to Its Hold Rating for Kezar Life Sciences (KZR)
Kezar stock falls 11% after board rejects Concentra offer (update)
Kezar discontinues development of zetomipzomib for lupus nephritis
Kezar stock falls 9% after board rejects Concentra takeover offer
Kezar board rejects Concentra proposal, adopts stockholder rights plan